199 related articles for article (PubMed ID: 22899868)
41. Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.
Watterson SH; De Lucca GV; Shi Q; Langevine CM; Liu Q; Batt DG; Beaudoin Bertrand M; Gong H; Dai J; Yip S; Li P; Sun D; Wu DR; Wang C; Zhang Y; Traeger SC; Pattoli MA; Skala S; Cheng L; Obermeier MT; Vickery R; Discenza LN; D'Arienzo CJ; Zhang Y; Heimrich E; Gillooly KM; Taylor TL; Pulicicchio C; McIntyre KW; Galella MA; Tebben AJ; Muckelbauer JK; Chang C; Rampulla R; Mathur A; Salter-Cid L; Barrish JC; Carter PH; Fura A; Burke JR; Tino JA
J Med Chem; 2016 Oct; 59(19):9173-9200. PubMed ID: 27583770
[TBL] [Abstract][Full Text] [Related]
42. Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis.
Lechner KS; Neurath MF; Weigmann B
J Mol Med (Berl); 2020 Oct; 98(10):1385-1395. PubMed ID: 32808093
[TBL] [Abstract][Full Text] [Related]
43. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
44. Substrate recognition of PLCγ1 via a specific docking surface on Itk.
Xie Q; Joseph RE; Fulton DB; Andreotti AH
J Mol Biol; 2013 Feb; 425(4):683-96. PubMed ID: 23219468
[TBL] [Abstract][Full Text] [Related]
45. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
46. Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.
Deng M; Zha J; Jiang Z; Jia X; Shi Y; Li P; Chen XL; Fang Z; Du Z; Xu B
J Transl Med; 2018 Feb; 16(1):47. PubMed ID: 29490645
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of type I insulin-like growth factor receptor tyrosine kinase by picropodophyllin induces apoptosis and cell cycle arrest in T lymphoblastic leukemia/lymphoma.
Huang Z; Fang Z; Zhen H; Zhou L; Amin HM; Shi P
Leuk Lymphoma; 2014 Aug; 55(8):1876-83. PubMed ID: 24206093
[TBL] [Abstract][Full Text] [Related]
48. Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.
Zapf CW; Gerstenberger BS; Xing L; Limburg DC; Anderson DR; Caspers N; Han S; Aulabaugh A; Kurumbail R; Shakya S; Li X; Spaulding V; Czerwinski RM; Seth N; Medley QG
J Med Chem; 2012 Nov; 55(22):10047-63. PubMed ID: 23098091
[TBL] [Abstract][Full Text] [Related]
49. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
[TBL] [Abstract][Full Text] [Related]
50. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
[TBL] [Abstract][Full Text] [Related]
51. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
52. Sequential phosphorylation of SLP-76 at tyrosine 173 is required for activation of T and mast cells.
Sela M; Bogin Y; Beach D; Oellerich T; Lehne J; Smith-Garvin JE; Okumura M; Starosvetsky E; Kosoff R; Libman E; Koretzky G; Kambayashi T; Urlaub H; Wienands J; Chernoff J; Yablonski D
EMBO J; 2011 Jul; 30(15):3160-72. PubMed ID: 21725281
[TBL] [Abstract][Full Text] [Related]
53. Andrographolide inhibits growth of human T-cell acute lymphoblastic leukemia Jurkat cells by downregulation of PI3K/AKT and upregulation of p38 MAPK pathways.
Yang T; Yao S; Zhang X; Guo Y
Drug Des Devel Ther; 2016; 10():1389-97. PubMed ID: 27114702
[TBL] [Abstract][Full Text] [Related]
54. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling.
Mera WA; Alzihlif M; Taha MO; Khanfar MA
Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297
[TBL] [Abstract][Full Text] [Related]
55. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
Fry DW; Bridges AJ; Denny WA; Doherty A; Greis KD; Hicks JL; Hook KE; Keller PR; Leopold WR; Loo JA; McNamara DJ; Nelson JM; Sherwood V; Smaill JB; Trumpp-Kallmeyer S; Dobrusin EM
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):12022-7. PubMed ID: 9751783
[TBL] [Abstract][Full Text] [Related]
56. Zebrafish screen identifies novel compound with selective toxicity against leukemia.
Ridges S; Heaton WL; Joshi D; Choi H; Eiring A; Batchelor L; Choudhry P; Manos EJ; Sofla H; Sanati A; Welborn S; Agarwal A; Spangrude GJ; Miles RR; Cox JE; Frazer JK; Deininger M; Balan K; Sigman M; Müschen M; Perova T; Johnson R; Montpellier B; Guidos CJ; Jones DA; Trede NS
Blood; 2012 Jun; 119(24):5621-31. PubMed ID: 22490804
[TBL] [Abstract][Full Text] [Related]
57. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
58. Regulated association between the tyrosine kinase Emt/Itk/Tsk and phospholipase-C gamma 1 in human T lymphocytes.
Perez-Villar JJ; Kanner SB
J Immunol; 1999 Dec; 163(12):6435-41. PubMed ID: 10586033
[TBL] [Abstract][Full Text] [Related]
59. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
60. Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).
Norman P
Expert Opin Ther Pat; 2014 Sep; 24(9):979-91. PubMed ID: 24990480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
